QuidelOrtho Corporation $QDEL Stake Cut by Beaconlight Capital LLC

Beaconlight Capital LLC lessened its holdings in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 36.4% during the 1st quarter, HoldingsChannel reports. The fund owned 152,057 shares of the company’s stock after selling 86,992 shares during the period. QuidelOrtho accounts for approximately 1.3% of Beaconlight Capital LLC’s portfolio, making the stock its 21st biggest holding. Beaconlight Capital LLC’s holdings in QuidelOrtho were worth $2,498,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Global Retirement Partners LLC boosted its holdings in shares of QuidelOrtho by 3,691.7% during the fourth quarter. Global Retirement Partners LLC now owns 910 shares of the company’s stock worth $26,000 after purchasing an additional 886 shares during the period. Camelot Portfolios LLC acquired a new stake in shares of QuidelOrtho during the 4th quarter valued at $29,000. Hantz Financial Services Inc. grew its holdings in shares of QuidelOrtho by 50.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock valued at $31,000 after acquiring an additional 362 shares in the last quarter. Larson Financial Group LLC grew its holdings in shares of QuidelOrtho by 322.2% during the 3rd quarter. Larson Financial Group LLC now owns 1,330 shares of the company’s stock valued at $39,000 after acquiring an additional 1,015 shares in the last quarter. Finally, Leonteq Securities AG increased its stake in shares of QuidelOrtho by 555.2% in the first quarter. Leonteq Securities AG now owns 3,466 shares of the company’s stock worth $57,000 after acquiring an additional 2,937 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Stock Performance

Shares of QDEL opened at $16.05 on Friday. The company has a market capitalization of $1.09 billion, a PE ratio of -0.90 and a beta of 0.69. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80. QuidelOrtho Corporation has a one year low of $9.92 and a one year high of $35.58. The company’s fifty day moving average price is $14.87 and its 200 day moving average price is $18.72.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The firm had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The firm’s revenue was down 10.5% on a year-over-year basis. During the same quarter last year, the company earned $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. As a group, analysts expect that QuidelOrtho Corporation will post 1.87 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on QDEL shares. Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research report on Friday, July 17th. UBS Group reaffirmed a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a research note on Thursday, May 7th. Jefferies Financial Group reiterated a “hold” rating on shares of QuidelOrtho in a report on Monday, June 29th. Finally, Citigroup boosted their price target on QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Four equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, QuidelOrtho currently has an average rating of “Reduce” and a consensus target price of $13.62.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.